Growth & profitability
- Revenue has grown 73.4% per year over the past 5 years.
Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
PRLD Financials Prelude Therapeutics Inc
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $12M | -$100M | 0.0% | -861.3% | -$56M | — | $35M |
| 2024 | $7M | -$127M | 0.0% | -1995.9% | -$104M | — | $12M |
| 2023 | — | -$122M | — | — | -$111M | — | $25M |
| 2022 | — | -$115M | — | — | -$87M | — | $31M |
| 2021 | — | -$112M | — | — | -$86M | — | $32M |
| 2020 | — | -$57M | — | — | -$47M | — | $218M |
| 2019 | — | -$28M | — | — | -$26M | — | $19M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $5M | -$10M | 0.0% | -309.5% | -$22M | — | $22M |
| Dec '25 | $6M | -$16M | 0.0% | -307.6% | $23M | — | $35M |
| Sep '25 | $7M | -$20M | 0.0% | -314.1% | -$19M | — | $48M |
| Jun '25 | — | -$31M | — | — | -$26M | — | $26M |
| Mar '25 | $0 | -$32M | — | — | -$34M | — | $40M |
| Dec '24 | $4M | -$29M | 0.0% | -845.8% | -$21M | — | $12M |
| Sep '24 | $3M | -$32M | 0.0% | -1145.9% | -$27M | — | $11M |
| Jun '24 | — | -$35M | — | — | -$23M | — | $28M |
| Mar '24 | — | -$31M | — | — | -$32M | — | $25M |
| Dec '23 | — | -$33M | — | — | -$25M | — | $25M |
| Sep '23 | — | -$31M | — | — | -$26M | — | $16M |
| Jun '23 | — | -$30M | — | — | -$29M | — | $26M |
| Mar '23 | — | -$28M | — | — | -$31M | — | $18M |
| Dec '22 | — | -$29M | — | — | -$23M | — | $31M |
| Sep '22 | — | -$30M | — | — | -$21M | — | $52M |
| Jun '22 | — | -$27M | — | — | -$19M | — | $51M |
| Mar '22 | — | -$29M | — | — | -$23M | — | $52M |
| Dec '21 | — | -$33M | — | — | -$26M | — | $32M |
| Sep '21 | — | -$31M | — | — | -$22M | — | $61M |
| Jun '21 | — | -$27M | — | — | -$20M | — | $343M |
Valuation over time
How the market has priced PRLD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 13.9× (Dec '24) to 26.9× (Jun '26).
P/S
Frequently asked questions
Is PRLD growing its revenue and profit?
Over the past 5 years, Prelude Therapeutics Inc's revenue has grown 73.4% per year. These are computed facts, not advice.
How much debt does PRLD have?
As of FY2025, Prelude Therapeutics Inc reported — of total debt against $35M of cash.
What is PRLD's profit margin?
In FY2025, gross margin was —, operating margin -861.3%, and net margin -819.6%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.